Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Genetic Signatures Ltd. ( (AU:GSS) ) has provided an update.
Genetic Signatures Ltd. reported a transformative year with a 63% increase in revenue to $15.9 million, driven by strong respiratory sales in Australia. The company reduced its underlying loss by 28% to $12.7 million, despite a statutory loss of $20.1 million due to a $7.0 million impairment. Strategic partnerships with Tecan Group and Repado aim to launch a next-generation automated solution, while the first US commercial contract marks a significant market entry. The company is focusing on core business pillars, streamlining its product portfolio, and enhancing automation, positioning itself for sustainable growth and innovation in molecular diagnostics.
The most recent analyst rating on (AU:GSS) stock is a Buy with a A$0.65 price target. To see the full list of analyst forecasts on Genetic Signatures Ltd. stock, see the AU:GSS Stock Forecast page.
More about Genetic Signatures Ltd.
Genetic Signatures Ltd. is a global molecular diagnostics company specializing in the development of innovative diagnostic solutions. The company focuses on providing advanced detection kits and systems, particularly in high-value disease areas and markets, to enhance manufacturing scalability and commercial momentum.
Average Trading Volume: 119,632
Technical Sentiment Signal: Sell
Current Market Cap: A$67.01M
See more data about GSS stock on TipRanks’ Stock Analysis page.